Navigation Links
Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
Date:10/27/2008

>Shareholders' equity:

Common stock 113,013 109,031

Retained earnings (accumulated deficit) 3,106 (2,967)

Accumulated other comprehensive loss (393) (1,415)

Total shareholders' equity 115,726 104,649

Total liabilities and shareholders' equity $132,057 $120,903

Non-GAAP Operating Income Per Share

(In thousands, except per share data)

Three Months Ended Six Months Ended

September 30, September 30,

2008 2007 2008 2007

Shares used in the calculation of

operating income per share (non-

GAAP):

Weighted average common shares

outstanding - basic 21,779 21,448 21,757 21,380

Weighted average common shares

outstanding - diluted 22,304 22,110 22,363 22,103

Non-GAAP operating income per share -

basic $0.22 $0.19 $0.41 $0.40

Non-GAAP operating income per share -

diluted $0.22 $0.19 $0.39 $0.39

Revenues by Geographic Region

(In thousands)

Three Months Ended Six Months Ended

September 30, September 30,

2008 2007 2008 2007

North America $22,482 $21,071 $42,777 $40,240

International 5,206 4,121 9,483 7,883

Total revenues $27,688 $25,192 $52,260 $48,123

Revenues by Customer Group

(In thousands)

Three Months Ended Six Months Ended


'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
2. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
9. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
10. Aware, Inc. Reports Third Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 ... sciences company focused on developing diagnostic tests for cancer and ... cancer study will be presented at the Science for Business ... Belgium . The data come from VolitionRx,s ... at the Pneumology department of the Centre Hospitalier Universitaire (CHU) ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
Breaking Biology Technology:VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... Presentation Scheduled for Monday, March 17th at 11:30am ET, ... KERX ) today announced that I. Craig Henderson, ... Vice President,Medical Affairs, are scheduled to present at the ... The presentation, which will take place on Monday, ...
... Phase 2 Clinical Trial in ... ... today financial results for the year ended December,31, 2007, and highlighted the ... ), During 2007, the Company achieved the following corporate milestones:, ...
... for ... cars, phones, computers, ARGONNE, Ill., ... Laboratory and Toda Kogyo Corp. (Toda) of Japan have,reached a ... patented composite cathode materials for lithium-ion,batteries, which result in longer-lasting, ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3
(Date:11/5/2014)... Fidel Santamaria, associate professor of biology in the ... researchers in the nation selected to receive a ... Grant for Exploratory Research (EAGER). The funding supports ... support researchers to create new technology that will ... Santamaria, complex behaviors in neuroscience are broken into ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... PHOENIX, Ariz. Feb. 5, 2010 The Translational ... a strategic alliance and affiliation agreement with the Van ... capabilities of both non-profit institutes. TGen expects ... aimed at developing new tests and treatments for patient ...
... study of children in Ukraine has found that for ... care and the relationship between children and their caregivers ... their findings, the researchers highlight the importance of comprehensive ... changing caregivers, working schedules and providing training to enhance ...
... Mich. In an effort to eliminate the tropical ... researcher has been awarded $2 million to reformulate an ... their tracks. Charles Mackenzie, a professor of veterinary ... the funding via a larger $13 million grant the ...
Cached Biology News:TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3For HIV-infected children, quality of caregiver relationship is crucial 2MSU researcher awarded $2 million to tackle parasitic tropical diseases 2
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
... FluoroGuard antifade reagent is ... confocal and standard fluorescence microscopy. ... photobleaching in a wide variety ... labeled with fluorescein, rhodamine, sulforhodamine ...
... UN-SCAN-IT gel Software converts any scanner ... has numerous options and features, the basic ... (TIFF, JPEG, PCX, BMP, etc.) into pixel ... simple steps. Turn your ...
... RED Chromogen System consists of FAST RED ... in the presence of alkaline phosphatase to ... The FAST RED System provides enough ... Contains: , , Vial A: 6 Tablets ...
Biology Products: